GlassScriptPhysician profile
Shannon L Smith
NPI 1114799202
$1,800.56
in general payments reported to CMS, 2019-2025
31 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $517 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $250.59 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $149.69 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $141.07 | 2024-2025 | Otezla, Repatha, Evenity |
| Lundbeck LLC | $100.25 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.93 | 2024-2025 | Xifaxan, Relistor |
| Corcept Therapeutics | $86.07 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $85.08 | 2025 | Airsupra, Breztri, Farxiga |
| Sumitomo Pharma America, INC. | $71.47 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $68.41 | 2024-2025 | |
| Madrigal Pharmaceuticals | $67.89 | 2025 | Rezdiffra |
| Teva Pharmaceuticals USA, INC. | $60.92 | 2025 | Austedo Xr |
| Esperion Therapeutics, INC. | $59.28 | 2024-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $57.77 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $51.79 | 2025 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $45.20 | 2024-2025 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $44.85 | 2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $43.96 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $39.54 | 2025 | |
| Edwards Lifesciences Corporation | $38.16 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novo Nordisk INC | $33.25 | 2025 | Ozempic |
| Abbvie INC. | $24.23 | 2025 | |
| Paratek Pharmaceuticals, INC. | $24.14 | 2025 | Nuzyra |
| Amneal Pharmaceuticals LLC | $22.53 | 2024 | Ongentys 50mg Capsules 30 |
| Dexcom, INC. | $22.07 | 2024 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $20.53 | 2025 | |
| Neurelis, INC. | $19.35 | 2024 | Valtoco |
| Alnylam Pharmaceuticals INC. | $19.30 | 2025 | Amvuttra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.89 | 2025 | Caplyta |
| Azurity Pharmaceuticals, INC. | $15.28 | 2025 | Azmiro |
| Kowa Pharmaceuticals America, INC. | $13.64 | 2025 | Zoryve |
| Axsome Therapeutics, INC. | $13.43 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.